Whitehawk Therapeutics, Inc. (WHWK)
3.07
+0.05
(+1.66%)
USD |
NASDAQ |
Nov 06, 10:20
Whitehawk Therapeutics Enterprise Value : -17.81M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -17.81M |
| November 04, 2026 | -9.264M |
| November 03, 2026 | -13.25M |
| November 02, 2026 | -12.11M |
| October 30, 2026 | -5.273M |
| October 29, 2026 | -1.852M |
| October 28, 2026 | 7.269M |
| October 27, 2026 | -0.142M |
| October 26, 2026 | -10.97M |
| October 23, 2026 | -6.983M |
| October 22, 2026 | -4.703M |
| October 21, 2026 | -2.707M |
| October 20, 2026 | -8.123M |
| October 19, 2026 | -18.38M |
| October 16, 2026 | -25.23M |
| October 15, 2026 | -16.67M |
| October 14, 2026 | -20.67M |
| October 13, 2026 | -17.81M |
| October 12, 2026 | 2.708M |
| October 09, 2026 | 10.69M |
| October 08, 2026 | 7.839M |
| October 07, 2026 | 4.419M |
| October 06, 2026 | 15.82M |
| October 05, 2026 | 20.95M |
| October 02, 2026 | 20.95M |
| Date | Value |
|---|---|
| October 01, 2026 | 24.37M |
| September 30, 2026 | 24.37M |
| September 29, 2026 | 22.66M |
| September 28, 2026 | 24.37M |
| September 25, 2026 | 23.23M |
| September 24, 2026 | 30.07M |
| September 23, 2026 | 27.79M |
| September 22, 2026 | 40.33M |
| September 21, 2026 | 40.33M |
| September 18, 2026 | 49.46M |
| September 17, 2026 | 42.61M |
| September 16, 2026 | 40.33M |
| September 15, 2026 | 43.18M |
| September 14, 2026 | 42.04M |
| September 11, 2026 | 44.32M |
| September 10, 2026 | 42.04M |
| September 09, 2026 | 48.89M |
| September 08, 2026 | 60.29M |
| September 04, 2026 | 72.26M |
| September 03, 2026 | 73.97M |
| September 02, 2026 | 78.53M |
| September 01, 2026 | 73.97M |
| August 31, 2026 | 68.84M |
| August 28, 2026 | 73.40M |
| August 27, 2026 | 87.65M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 539.10M |
| Amgen, Inc. | 289.78B |
| Anika Therapeutics, Inc. | 245.53M |
| BioCryst Pharmaceuticals, Inc. | 2.407B |
| Imunon, Inc. | 5.181M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.64M |
| Total Expenses (Quarterly) | 16.64M |
| EPS Diluted (Quarterly) | -0.2008 |
| Earnings Yield | -36.28% |
| Normalized Earnings Yield | -36.28 |